What: ImmunoGen (NASDAQ:IMGN) reported its fiscal third-quarter earnings on Friday, and fell as much as 22%, but it wasn't the biotech's revenue or loss that has investors hitting the sell button.
So what: For the record, ImmunoGen reported revenue of $19.7 million, up from $11.4 million in the year-ago quarter, thanks to a $10 million milestone earned from its partner Bayer. And the biotech lost $31.9 million, more than the $21.6 million it lost a year ago -- but still completely reasonable given that ImmonGen has $182.9 million sitting in the bank.
Instead of the earnings numbers, it appears that investors are concerned with ImmunoGen's disclosure of its plan to change the design of the next clinical trial for its lead-pipeline candidate, mirvetuximab soravtansine. The ovarian cancer trial, dubbed FORWARD I, was previously designed as a two-stage, phase II trial with response rate as the primary endpoint, but ImmunoGen has decided to change it to a single-stage phase 3 trial with progression-free survival as the primary endpoint.
There are a couple of changes here, so let's break it down:
- The new trial design will enroll patients who are earlier in their ovarian cancer disease progression because patients with three or fewer treatment regimens appear to have a better response rate in the phase 1 trial.
- There were some side effects associated with the drug that might have made it more appropriate as a later-stage drug -- and the reason for the previous two-stage design -- but doctors have figured out how to manage those side effects, making it easier to tolerate a stronger dose for earlier-stage patients.
- The old trial was designed to facilitate an accelerated FDA approval, which requires more data to gain full approval, while the new design would result in full approval if the data is positive.
- The change from response rate to progression-free survival as the primary endpoint makes more sense given the earlier population, and facilitates the aforementioned ability to gain a full approval. ImmunoGen hopes mirvetuximab soravtansine can produce progression-free survival of six months, compared to 3.5 months to four months for current therapies at this stage of disease progression.
- The larger trial with longer follow-up will add about six months onto the trial compared to the previous design.
If the new trial produces positive data, the changes will end up being a good move because the number of potential patients in the U.S. increases to 5,000 to 7,000 compared to 2,000 to 3,000 with the old enrollment criteria.
But there are risks associated with the change because ImmunoGen is generating a hypothesis based on a subset of the patients in the earlier trial, and testing the hypothesis in the FORWARD I trial. Investors are worried that the observed benefit by earlier-stage patients is just an artifact.
That view is confounded by management's disclosure that the response rate in the overall population of the phase 1 trial is "a little below 30%" compared to a response rate of 35% that was previously disclosed for the first set of patients enrolled in the phase 1 trial. Management hinted that the subset of phase 1 patients who would be eligible for the new phase 3 had a higher response rate; but we'll have to wait until the American Society of Clinical Oncology (ASCO) meeting in June to see the breakdown of the data.
Now what: This summer, investors will be focused on the ASCO data, while management will be working toward getting the new trial design approved by the Food and Drug Administration. Assuming the FDA signs off, ImmunoGen thinks it can start enrollment in FORWARD I by the end of the year, so it'll be awhile before we get the data, and know if investors are overreacting to the changes.
Beyond mirvetuximab soravtansine, management updated investors on the rest of the company's pipeline. The phase 1 trial for IMGN779 in patients with acute myeloid leukemia has begun enrolling patients. And the company expects to start enrolling shortly for the phase 2 trial testing IMGN529 in combination with rituximab in diffuse large B-cell lymphoma.
With no meaningful revenue, ImmunoGen remains a waiting game, albeit one that may have a little less certainty after today's announcement.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends ImmunoGen. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.